Lianhua Qingwen Capsule/Granule (hereinafter referred to as LHQW) is a new Chinese patent medicine (SFDA Approval No.: Z20040063) developed under the guidance of collateral disease theory in traditional Chinese medicine (TCM) for the treatment of cold and influenza. LHQW is the first new medicine approved through fast-track approval process by the National Medical Products Administration during the SARS epidemic, has been awarded with
On March 3, the Standard Therapy for Novel Coronavirus Pneumonia (Version VII, Tentative) was published by the National Health Commission and the National Administration of Traditional Chinese Medicine together. Ever since the outbreak of the epidemic disease, there have been 5 versions of the national standard therapy that recommended the use of TCM patent drugs and all of them recommended the use of Lianhua Qingwen Capsules and Granules to be used for the treatment during the medical observation period.
The Standard Therapy for Novel Coronavirus Pneumonia (Version IV, Tentative) has been published by the National Health Commission and the National Administration of Traditional Chinese Medicine together in order to effectively control the current epidemic event and practically protect the health of the people. And Lianhua Qingwen Capsules/Granules have been listed as recommended products to be used during the medical observation period. What is the population during the medical observation period? What roles can Lianhua Qingwen play in this population? How shall Lianhua Qingwen be used?
Recently, the Expert Consensus Document on Diagnosis, Treatment and Prevention of Novel Coronavirus Infections in Children (Version I) (hereinafter referred to as the Expert Consensus) was prepared by the National Clinical Medicine Study Center on Respiratory Diseases, the Children's National Medical Center, and the Group of Respiratory Diseases of Society of Pediatrics of Chinese Medical Association. In this Expert Consensus Lianhua Qingwen Granules is recommended for the treatment of such symptoms as weakness, fever, sore throat and dry coughing during the medical observation period for children infected by novel coronavirus.